US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Shooting injures 2 at Missouri high school graduation ceremony
CAPE GIRARDEAU, Mo. (AP) — Two people were injured when gunfire broke out during a high school gradu2024-05-21China to Further Enhance Medical Treatment for Critical Pregnant Women
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Gains Made in Reducing School Stress
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Across China: Tourism Rejuvenates Ancient Korean Ethnic Folk Village
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Kate Hudson hits the stage to debut songs from her new album Glorious at star
Kate Hudson looked like a pro as she performed songs from her new album Glorious for the first time.2024-05-21People Prepare for Upcoming Chinese New Year Across China
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment